Adult Myopia Market

Market Overview:

The 7 major adult myopia markets reached a value of US$ 177.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 256.9 Million by 2034, exhibiting a growth rate (CAGR) of 3.44% during 2024-2034.

The adult myopia market has been comprehensively analyzed in IMARC's new report titled "Adult Myopia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adult myopia, also known as nearsightedness, is a common refractive eye disorder that affects individuals typically after the age of 18. In this condition, the eye's focusing power is stronger for nearby objects, making distant objects appear blurry. Myopia occurs when the eyeball is too long or the cornea's curvature is too steep, causing light beams to focus in front of the retina instead of directly on it. The symptoms of the ailment include difficulty seeing distant objects clearly, squinting, eye strain, headaches, and a tendency to sit or stand close to the TV or other screens. Individuals suffering from this illness might also face challenges in activities, such as driving, especially at night. Diagnosing adult myopia is usually done through a detailed eye exam conducted by an optometrist or ophthalmologist. The healthcare provider will also perform various workups, including a visual acuity test, a refraction test, and a comprehensive analysis of the eye's structure.

The increasing incidence of various associated risk factors, such as excessive near work, prolonged screen time, limited outdoor activities, etc., resulting in eye strain and elongation of the eyeball, is primarily driving the adult myopia market. In addition to this, the growing awareness among the population about the importance of vision correction and the availability of effective treatments is also creating a positive outlook for the market. Moreover, the widespread adoption of innovative treatments, such as orthokeratology, which involves wearing specialized gas permeable contact lenses to retain the shape of the cornea and correct myopia in individuals suffering from the ailment, is further bolstering the market growth. This non-invasive procedure helps to enhance visual acuity and slow down the disease's progression. Additionally, the inflating application of corneal collagen cross-linking therapy, that uses ultraviolet A (UVA) light and a photosensitizing riboflavin solution to strengthen chemical bonds in the cornea of the eye, thereby preventing further deterioration in patients, is acting as another significant growth-inducing factor. Besides this, the emerging popularity of gene therapy, which entails the insertion of corrective genes to rectify the aberrant genetic material responsible for the underlying condition, is expected to drive the adult myopia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the adult myopia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adult myopia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adult myopia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the adult myopia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the adult myopia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current adult myopia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the adult myopia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the adult myopia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the adult myopia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of adult myopia across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of adult myopia by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of adult myopia by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with adult myopia across the seven major markets?
• What is the size of the adult myopia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of adult myopia?
• What will be the growth rate of patients across the seven major markets?
   

Adult Myopia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for adult myopia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adult myopia market?
• What are the key regulatory events related to the adult myopia market?
• What is the structure of clinical trial landscape by status related to the adult myopia market?
• What is the structure of clinical trial landscape by phase related to the adult myopia market?
• What is the structure of clinical trial landscape by route of administration related to the adult myopia market?